The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1

CYP2D6 plays a major role in the metabolism of tamoxifen, and polymorphism of P-glycoprotein has been associated with resistance of many drug therapies. This study investigates the clinical impact of genetic variants of CYP2D6 and ABCB1 in breast cancer patients treated with tamoxifen. Blood samples...

Full description

Bibliographic Details
Published in:AAPS Journal
Main Author: Teh L.K.; Mohamed N.I.; Salleh M.Z.; Rohaizak M.; Shahrun N.S.; Saladina J.J.; Shia J.K.S.; Roslan H.; Sood S.; Rajoo T.S.; Muniandy S.P.; Henry G.; Ngow H.A.; Hla U K.T.; Din J.
Format: Article
Language:English
Published: 2012
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84857627005&doi=10.1208%2fs12248-011-9313-6&partnerID=40&md5=eea28b3b2f6906aaed8c5112ae07b2b9
id 2-s2.0-84857627005
spelling 2-s2.0-84857627005
Teh L.K.; Mohamed N.I.; Salleh M.Z.; Rohaizak M.; Shahrun N.S.; Saladina J.J.; Shia J.K.S.; Roslan H.; Sood S.; Rajoo T.S.; Muniandy S.P.; Henry G.; Ngow H.A.; Hla U K.T.; Din J.
The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1
2012
AAPS Journal
14
1
10.1208/s12248-011-9313-6
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84857627005&doi=10.1208%2fs12248-011-9313-6&partnerID=40&md5=eea28b3b2f6906aaed8c5112ae07b2b9
CYP2D6 plays a major role in the metabolism of tamoxifen, and polymorphism of P-glycoprotein has been associated with resistance of many drug therapies. This study investigates the clinical impact of genetic variants of CYP2D6 and ABCB1 in breast cancer patients treated with tamoxifen. Blood samples from 95 breast cancer patients treated with tamoxifen were collected and genotyped for CYP2D6 and ABCB1 variants using allele-specific PCR method. Recurrence risks were calculated using Kaplan-Meier analysis and compared using the log-rank test. Patients carrying CYP2D6*10/*10 and heterozygous null allele (IM) showed higher risks of developing recurrence and metastasis (OR 13.14; 95% CI 1.57-109.94; P=0.004) than patients with CYP2D6*1/*1 and*1/*10 genotypes. Patients with homozygous CC genotypes of ABCB1 C3435T showed a shorter time to recurrence. Patients who were CYP2D6 IM and homozygous CC genotype of C3435T have statistically significant higher risks of recurrence (P=0.002). Similarly, median time to recurrence in these patients was only 12 months (95% CI=0.79-23.2) compared to those without this combination which was 48 months (95% CI=14.7-81.2). Patients with CYP2D6 IM and homozygous CC genotype of ABCB1 C3435T have shorter times to recurrence. The results confirmed the findings of previous studies and support FDA recommendation to perform pre-genotyping in patients before the choice of therapy is determined in breast cancer patients. © 2011 American Association of Pharmaceutical Scientists.

15507416
English
Article
All Open Access; Green Open Access
author Teh L.K.; Mohamed N.I.; Salleh M.Z.; Rohaizak M.; Shahrun N.S.; Saladina J.J.; Shia J.K.S.; Roslan H.; Sood S.; Rajoo T.S.; Muniandy S.P.; Henry G.; Ngow H.A.; Hla U K.T.; Din J.
spellingShingle Teh L.K.; Mohamed N.I.; Salleh M.Z.; Rohaizak M.; Shahrun N.S.; Saladina J.J.; Shia J.K.S.; Roslan H.; Sood S.; Rajoo T.S.; Muniandy S.P.; Henry G.; Ngow H.A.; Hla U K.T.; Din J.
The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1
author_facet Teh L.K.; Mohamed N.I.; Salleh M.Z.; Rohaizak M.; Shahrun N.S.; Saladina J.J.; Shia J.K.S.; Roslan H.; Sood S.; Rajoo T.S.; Muniandy S.P.; Henry G.; Ngow H.A.; Hla U K.T.; Din J.
author_sort Teh L.K.; Mohamed N.I.; Salleh M.Z.; Rohaizak M.; Shahrun N.S.; Saladina J.J.; Shia J.K.S.; Roslan H.; Sood S.; Rajoo T.S.; Muniandy S.P.; Henry G.; Ngow H.A.; Hla U K.T.; Din J.
title The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1
title_short The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1
title_full The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1
title_fullStr The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1
title_full_unstemmed The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1
title_sort The risk of recurrence in breast cancer patients treated with tamoxifen: Polymorphisms of CYP2D6 and ABCB1
publishDate 2012
container_title AAPS Journal
container_volume 14
container_issue 1
doi_str_mv 10.1208/s12248-011-9313-6
url https://www.scopus.com/inward/record.uri?eid=2-s2.0-84857627005&doi=10.1208%2fs12248-011-9313-6&partnerID=40&md5=eea28b3b2f6906aaed8c5112ae07b2b9
description CYP2D6 plays a major role in the metabolism of tamoxifen, and polymorphism of P-glycoprotein has been associated with resistance of many drug therapies. This study investigates the clinical impact of genetic variants of CYP2D6 and ABCB1 in breast cancer patients treated with tamoxifen. Blood samples from 95 breast cancer patients treated with tamoxifen were collected and genotyped for CYP2D6 and ABCB1 variants using allele-specific PCR method. Recurrence risks were calculated using Kaplan-Meier analysis and compared using the log-rank test. Patients carrying CYP2D6*10/*10 and heterozygous null allele (IM) showed higher risks of developing recurrence and metastasis (OR 13.14; 95% CI 1.57-109.94; P=0.004) than patients with CYP2D6*1/*1 and*1/*10 genotypes. Patients with homozygous CC genotypes of ABCB1 C3435T showed a shorter time to recurrence. Patients who were CYP2D6 IM and homozygous CC genotype of C3435T have statistically significant higher risks of recurrence (P=0.002). Similarly, median time to recurrence in these patients was only 12 months (95% CI=0.79-23.2) compared to those without this combination which was 48 months (95% CI=14.7-81.2). Patients with CYP2D6 IM and homozygous CC genotype of ABCB1 C3435T have shorter times to recurrence. The results confirmed the findings of previous studies and support FDA recommendation to perform pre-genotyping in patients before the choice of therapy is determined in breast cancer patients. © 2011 American Association of Pharmaceutical Scientists.
publisher
issn 15507416
language English
format Article
accesstype All Open Access; Green Open Access
record_format scopus
collection Scopus
_version_ 1809678162157633536